Inotiv_Logo_CMYK.png
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
July 15, 2021 08:33 ET | Inotiv, Inc.
WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
ProgenityLogo.jpg
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
June 30, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July...
ProgenityLogo.jpg
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
June 15, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder...
K_Swart Headshot
Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings
May 11, 2021 16:05 ET | Inotiv, Inc.
WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Qu Biologics.png
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
December 18, 2020 13:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics.png
Qu Biologics Completes $8M Financing
December 09, 2020 06:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
September 29, 2020 08:00 ET | BioCardia, Inc.
SAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
logo.jpg
Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
June 23, 2020 07:00 ET | Codexis, Inc.
REDWOOD CITY, Calif. and SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular...
CDXS Elects New Independent Directors
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
June 16, 2020 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
July 31, 2018 07:00 ET | AnGes, Inc.
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes,...